Beyond Biotech - the podcast from Labiotech – Détails, épisodes et analyse

Détails du podcast

Informations techniques et générales issues du flux RSS du podcast.

Beyond Biotech - the podcast from Labiotech

Labiotech

Actualités

Fréquence : 1 épisode/7j. Total Éps: 208

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

Lire plusRéduire

Site

RSS

Apple

Classements récents

Dernières positions dans les classements Apple Podcasts et Spotify.

Apple Podcasts

🇬🇧 Grande Bretagne - techNews
23/08/2026
#83
🇺🇸 États-Unis - techNews
23/08/2026
#79
🇫🇷 France - techNews
23/08/2026
#29
🇬🇧 Grande Bretagne - techNews
22/08/2026
#69
🇺🇸 États-Unis - techNews
22/08/2026
#95
🇬🇧 Grande Bretagne - techNews
21/08/2026
#55
🇬🇧 Grande Bretagne - techNews
20/08/2026
#37
🇺🇸 États-Unis - techNews
16/08/2026
#88
🇺🇸 États-Unis - techNews
14/08/2026
#88
🇬🇧 Grande Bretagne - techNews
13/08/2026
#82

Spotify

Aucun classement récent disponible

Liens partagés entre épisodes et podcasts

Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.

https://www.labiotech.eu/advertise/
71 partages
https://www.labiotech.eu/newsletter/
69 partages
https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp
56 partages

Qualité et score du flux RSS

Évaluation technique de la qualité et de la structure du flux RSS.

Qualité du flux RSS

À améliorer

Score global : 37%

Historique des publications

Répartition mensuelle des publications d'épisodes au fil des années.

Year

Derniers épisodes publiés

Liste des épisodes récents, avec titres, durées et descriptions.

The power of tumor infiltrating lymphocytes to fight melanoma

vendredi 6 septembre 2024 • Durée 38:03

Tumor infiltrating lymphocyte (TIL) therapy uses a person’s own immune cells to fight advanced melanoma, offering new hope for patients who have limited treatment options.

This week, we have a conversation with Brian Gastman, EVP of medical affairs at Iovance Biotherapeutics, about TILs and the company’s pipeline.

Iovance recently submitted a marketing authorization application to the European Medicines Agency for lifileucel, a TIL cell therapy, for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.

If approved, lifileucel will be the first and only approved therapy in this treatment setting in all European Union member states.

The submission is supported by positive clinical data from the C-144-01 clinical trial in patients with advanced post-anti-PD1 melanoma.

Iovance’s Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication.

00:47-04:44: About Iovance Biotherapeutics
04:44-07:57: What is polyclonal tumor infiltrating lymphocyte treatment?
07:57-14:55: What is the production process for TILs?
14:55-18:32: Are there any limiting factors for TIL treatment?
18:32-20:59: Is early intervention important?
20:59-21:22: Does better psychology help?
21:22-22:06: Are other companies working on TILs?
22:06-27:25: Clinical trials
27:25-29:25: How do you address cost?
29:25-34:21: Iovance’s pipeline
34:21-35:30: Can TILs be improved?
35:30-37:21: Where does the TIL space go from here?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

Lire plusRéduire

The future of combination vaccines

vendredi 30 août 2024 • Durée 24:44

The development of combination vaccines could represent a significant advancement in the fight against infectious diseases. With the potential to streamline the vaccination process and provide broader protection, these vaccines could greatly improve public health preparedness.

Moderna is harnessing the power of its mRNA platform to develop vaccines that target multiple respiratory viruses at once, including COVID-19, RSV, and influenza. The breakthrough technology enables the immune system to combat multiple pathogens simultaneously, revolutionizing immunization efforts and enhancing public health preparedness.

To look at combination vaccines, their usefulness and potential for the future, we had an in-depth conversation with Cesar Sanz Rodriguez, vice president, Europe & Switzerland, medical affairs, at Moderna.

00:45-02:53: What is combination vaccine technology?
02:53-05:33: What are the advantages of targeting multiple respiratory diseases simultaneously?
05:33-06:02: Making vaccinations more friendly
06:02-07:57: How does the immune system handle tackling many pathogens at the same time?
07:57-10:23: Is there an effect of efficacy with combination vaccines?
10:23-12:50: How do you manage different times between boosters?
12:50-13:57: Are many companies working on combination vaccines?
13:57-17:45: How easy is it to add vaccines, for example to tackle avian flu, into combination vaccines?
17:45-19:06: Is there a limit to the number of vaccines in a combination vaccine?
19:06-20:46: How easily can vaccines be updated to address variants?
20:46-22:30: What is the future of combination vaccines?
22:30-23:56: What is in Moderna’s pipeline related to vaccines?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To learn more about the topic:

From pandemic spotlight to post-COVID crossroads: What happened to these biotech players?

Priovant - finding options to treat autoimmune diseases

vendredi 28 juin 2024 • Durée 30:05

US-based biotech company Priovant Therapeutics is dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options.

The company's lead asset, brepocitinib, is a dual selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib suppresses key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL6, IL12, and IL23—with a single, targeted therapy.

Brepocitinib has generated positive data in seven phase 2 studies with oral once-daily administration. It is currently being evaluated in a phase 3 program for dermatomyositis and is entering a phase 3 program for non-infectious uveitis.

This week on the podcast we have a conversation with Priovant’s CEO Benjamin Zimmer about dermatomyositis, non-infectious uveitis, current treatments, potential options, and how brepocitinib is making a difference.

00:55-02:34: About Priovant
02:34-06:38: What are dermatomyositis and non-infectious uveitis?
06:38-08:35: What are the current treatments?
08:35-12:32: What is brepocitinib?
12:32-15:36: Are there other treatments in development?
15:36-17:50: What is your relationship with Pfizer?
17:50-20:48: Brepocitinib clinical trials
20:48-24:06: Future plans and timeline
24:06-27:59: Finding patients for clinical trials
27:59-29:19: Future opportunities

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

Lire plusRéduire

Beyond Biotech podcast 12: Gate Neurosciences, Oncolyze, 3Brain

vendredi 2 septembre 2022 • Durée 56:29

2:48 Labiotech.eu news
5:22 Gate Neurosciences
16:18 3Brain
31:13 Oncolyze
50:22 JLL

This week’s podcast guests are Mike McCully, CEO of Gate Neurosciences; Steven Evans, CEO and co-founder of Oncolyze; and Philipp Markolin, scientific marketing specialist at 3Brain.

We also have our weekly chat with global commercial real estate services company JLL, and this week it’s a chat with Amber Schiada, head of life sciences research in the Americas for the company.

Gate launches to develop CNS treatments

Gate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders.

Gate, a U.S. biotech company, was founded in 2019 by a team of neuroscience industry veterans to address the need for more effective treatments for CNS disorders, and to overcome long-standing challenges in CNS drug development.

Since its founding, the company has acquired a portfolio of next-generation compounds from large pharma, along with corresponding data from thousands of patients dosed across numerous clinical trials that will inform and de-risk future development.

Oncolyze set for AML clinical trials

After successfully completing in vitro and in vivo experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer cells and increases survival rates, Oncolyze now has its sights set on advancing OM-301 into clinical trials.

Oncolyze has designed a novel anti-cancer drug (OM-301) that targets a particular cell surface protein. This protein, HDM2, is known to exist at high levels inside cancer cells and is thought to be an important driver of cancer growth and metastasis. More recently, though, it was discovered that HDM2 is also found on the cell surface of many types of cancer cells, but not normal cells. 3D microchip gives insights into human brain

Beyond Biotech podcast 11: Ilya Pharma, IRB Barcelona, Krystal Biotech, Phase Genomics

vendredi 26 août 2022 • Durée 58:34

2:15 Labiotech.eu news
5:12 Phase Genomics
16:44 IRB Barcelona
29:37 Ilya Pharma
43:00 Krystal Biotech
53:54 JLL

Our guests are Ilya Pharma CEO and co-founder Evelina Vågesjö and chief financial officer Oskar Lund; Miguel Martín-Álvarez, postdoctoral fellow in the cancer science unit at IRB Barcelona; Hubert Chen, head of clinical development at Krystal Biotech; and Ivan Liachko, CEO of Phase Genomics.

We also have a new weekly addition, as JLL will be joining us with a look at financial news. This week, we’re joined by Robert Coughlin, JLL managing director and New England Life Science Practice Group lead.

Study says gene editing with CRISPR/Cas9 can lead to cell toxicity and genome instability

CRISPR allows the introduction of a desired DNA sequence into (virtually) any spot of the genome, thus modifying or inactivating a gene. The technique is widely used in biomedical research and some CRISPR-based therapies are in clinical trials for the treatment of human blood disorders, some types of cancer and HIV.

Scientists at IRB Barcelona, led by ICREA researcher Fran Supek, have now reported that, depending on the targeted spot of the human genome, CRISPR gene editing can give rise to cell toxicity and genomic instability.

Ilya Pharma finalizes global patent coverage for modified lactic acid bacteria to treat wounds

Ilya Pharma, a Swedish clinical stage biopharma company focused on delivering local immunotherapies to patients, has announced the issue of four new patents.

These are: one in India, and continuation patents in China, Australia and the U.S. This means the company’s method for using modified bacteria for treatment of both mucosal and cutaneous wounds in humans and animals has patent protection in all major markets.

Ilya is currently developing a portfolio of three first-in-class immunotherapies for skin and mucosal diseases, including ILP100-Topical for treatment surgical wounds in diabetic, prediabetic and obese patients especially at risk, ILP100-Topical for diabetic ulcers and ILP100-Oral for patients with immune mediated enterocolitis resulting from cancer treatment with checkpoint inhibitors.

Beyond Biotech podcast 10: Endpoint Health, Nevrargenics, Triastek

vendredi 19 août 2022 • Durée 52:42

This week our guests on the podcast are Xianghao Zuo, deputy director of R&D at Triastek; Endpoint Health CEO Jason Springs; and Andy Whiting, CEO of Nevrargenics.

2:15 News
4:28 Nevrargenics
22:26 Triastek
37:14 Endpoint Health

Triastek and Lilly working together on 3D printing for drugs

A new research collaboration between Chinese company Triastek, Inc. and Eli Lilly and Company will leverage 3D printing technology to achieve precise targeting and programmed drug release in the intestine.

Triastek has developed 3D printing technology to provide solutions for drug development. According to the agreement, Triastek and Lilly will focus on improving the bioavailability of drugs in the intestine.

Triastek will first conduct in-depth studies of the excipient – inert ingredients added to a drug product for specific functional roles -- to ensure drug stability is maintained during development and 3D printing. Then, Triastek will identify the optimum 3D structure design for achieving targeted and programmed drug release.

Triastek has already received two investigational drug clearances from the U.S. Food and Drug Administration for its 3D printed drugs, T19 and T20.

Endpoint Health receives funding for precision immunology pipeline

Endpoint Health, Inc., a therapeutics company dedicated to addressing unmet needs in immune-mediated acute and chronic diseases, recently recveived $52 million in equity and debt financing.

Proceeds from the financing round are being used to extend the company’s Precision-First platform and expand its therapeutic pipeline to include programs for chronic immune-mediated diseases.

In addition, proceeds will be used to advance Antithrombin III, the company’s first precision therapy, to a phase II clinical trial for the treatment of sepsis. The company expects to submit its Investigational New Drug application and Investigational Device Exemption to the US Food and Drug Administration for its Antithrombin III program later this year.

Completion of the Series A financing follows Endpoint Health’s of a global collaboration and licensing agreement with Grifols to develop and commercialize Antithrombin III in sepsis.

Beyond Biotech podcast 9: ARCH Venture Partners, Micropep, PTC Therapeutics, Valneva

vendredi 12 août 2022 • Durée 55:01

This week's guests are ARCH Venture Partners’ managing director Kristina Burow; founder and CEO of Micropep Thomas Laurent; Kylie O’Keefe, SVP, commercial & corporate strategy at PTC Therapeutics, and Juan Carlos Jaramillo, chief medical officer of Valneva.

1:40 News
3:47 PTC
18:32 Micropep
33:01 Valneva
42:12 ARCH

ARCH Venture Partners closes $2.97B biotech fund

ARCH Venture Partners has announced the closing of ARCH Venture Fund XII, with $2.975 billion to invest in the creation, development and funding of early stage biotechnology companies.

ARCH Venture Partners is one of the largest early-stage technology venture firms in the U.S. It invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market.

Upstaza gets EC green light

PTC Therapeutics, Inc. says Upstaza (eladocagene exuparvovec) has been given marketing authorization by the European Commission.

Upstaza is the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency, and the first marketed gene therapy directly infused into the brain. It is approved for patients 18 months and older.

Upstaza also reduced symptoms that cause potentially life-threatening and morbid complications.

The marketing authorization is applicable to all 27 European Union member states, as well as Iceland, Norway and Liechtenstein.

Micropep raises €8.75M to develop alternative crop-protection products

French ag-biotech company Micropep, which develops biological micropeptide-based solutions for agriculture, has completed an €8.75 million ($9.3 million) series A1 financing round.

Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKARE

vendredi 5 août 2022 • Durée 01:00:51

This week’s podcast guests are Laura Fletcher, head of business development and strategic partnerships at Deep Science Ventures; Matthias Steger, CEO of Endogena Therapeutics; Rodolphe Besserve, CEO, and Georges Rawadi, chief of biotech studio development, at eureKARE; and Biotech Growth Trust portfolio manager, Geoff Hsu.

News: 02:30
Endogena Therapeutics 5:10
eureKARE 21:00
Deep Science Ventures 33:46
Biotech Growth Trust 47:44

Endogena Therapeutics Inc. has announced the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP).

RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of vision, for which there is currently no treatment for most patients. It is a leading cause of inherited blindness, with an estimated 1.5 million people worldwide presently affected.

eureKARE, an investment company focused on financing and building next generation biotech companies in the fields of synthetic biology, has launched its first synthetic biology studio in Belgium.

eureKARE is developing a pan-European biotech studio network covering several areas where synthetic biology can create solutions and high market value products.

The synthetic biology studios will focus on biomedical and other thematic applications in different European innovation hotspots. The strategy is based on identifying, selecting, and nurturing high-quality European science.

The venture builder Deep Science Ventures (DSV) has expanded an existing alliance with Cancer Research UK’s innovation-focused arm Cancer Research Horizons, with the mission to establish new oncology startups in the U.K.

Just months after Cancer Research UK (CRUK) established its industry-orientated division Cancer Research Horizons, the research charity has doubled down on a collaboration with DSV, a U.K. venture builder operating in a range of sectors including biotech, agriculture and computation.

Beyond Biotech podcast 7: World Hepatitis Day

vendredi 29 juillet 2022 • Durée 45:18

This week's podcast features three interviews related to hepatitis.

Our guests are Ahmed Elsharkawy, consultant transplant hepatologist and honorary senior clinical lecturer at the University of Birmingham in the UK; Ziv Ben-Ari, director of the Liver Diseases Center at the Sheba Medical Center in Israel, and James McIlroy, chief executive officer at EnteroBiotix.

World Hepatitis Day

Taking place on July 28 every year, World Hepatitis Day unites the world under a single theme to raise awareness of the global burden of viral hepatitis with the intention of influencing real change. This year’s theme is ‘I Can’t Wait’.

Dr Ahmed Elsharkawy is a consultant transplant hepatologist and honorary senior clinical lecturer at the University of Birmingham and he is also chair of hepatitis B virus special interest group which is part of the British Association for the Study of the Liver. He is a strong supporter and advocate of World Hepatitis Day.

Professor Ziv Ben-Ari is director of the Center for Liver Diseases and Liver Research Laboratory at the Sheba Medical Center in Israel and Professor of Medicine at Tel-Aviv University.

She has more than 25 years of experience in evaluating candidates for liver transplantation and monitoring liver transplants including five years as a fellow in Hepatology and Liver Transplantation at the Royal Free Hospital, London. She has chaired the Israeli Liver Research Society, chairs the Liver Committee of the National Council of Gastroenterology and is an active member of the American and European Association for the Study of the Liver. She has published more than 175 studies in leading medical journals.

Dr James McIlroy is a qualified medical doctor and biopharmaceutical entrepreneur widely recognized as a pioneer and thought leader in the application of the microbiome to treat disease.

He founded EnteroBiotix with the vision of building one of the world’s leading microbiome drug development companies.

Sponsor
Interested in sponsoring one or more episodes of the podcast? Learn more here!

Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma

vendredi 22 juillet 2022 • Durée 46:05

On this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach, and Eric Moessinger, both partners at +ND Capital; and Louise Modis, chief scientific officer at Mogrify.

Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority approval to commence its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment for severe influenza.

Biopharma company Mogrify Limited, and Japanese regenerative medicine firm Astellas Pharma Inc., have announced a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.

Belgian headquartered biotech Galapagos NV has acquired CellPoint and AboundBio, a move the Belgian company said propels it into next-generation cell therapy.

The deal saw the Lausanne-based team of US venture capital firm, +ND Capital, mark its second successful exit in the European biotech market.

Sponsor
Interested in sponsoring one or more episodes of the podcast? Learn more here!

Leave a review on Apple podcasts
Reviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!

Connect with us

Podcasts Similaires Basées sur le Contenu

Découvrez des podcasts liées à Beyond Biotech - the podcast from Labiotech. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !

À propos Méthodologie Contact Me soutenir Politique de confidentialité

Beyond Biotech - the podcast from Labiotech – Détails, épisodes et analyse

Détails du podcast

Classements récents

Apple Podcasts

Spotify

Liens partagés entre épisodes et podcasts

Other99+

Qualité et score du flux RSS

Historique des publications

Derniers épisodes publiés

Podcasts et contenus similaires

Podcasts Similaires Basées sur le Contenu

Podcasts Similaires Basées sur le Contenu

Other99+

Medium1

Apple Podcasts

Spotify